Department of Natural Science and Biomedicine, School of Health and Welfare, Jönköping University, Jönköping 551 11, Sweden.
Department of Laboratory Medicine and Pathology, Region Jönköping County, Jönköping 553 05, Sweden.
World J Gastroenterol. 2022 May 21;28(19):2148-2151. doi: 10.3748/wjg.v28.i19.2148.
The association between type 2 diabetes mellitus (DM) and colorectal cancer (CRC) has been thoroughly investigated and reports have demonstrated that the risk of CRC is increased in DM patients. The association between DM and the survival of patients with CRC is controversial. Evidence suggests that metformin with its anti-inflammatory effects is a protective factor against the development of CRC among DM patients and that metformin therapy is associated with a better prognosis in patients with DM. In our cohort, we did not find any associations between the presence of DM or metformin and cancer specific survival or any relation to plasma levels of a panel of 40 inflammatory factors and irisin. On the other hand, we identified that the insulin-like growth factor binding protein 7 single nucleotide polymorphism rs2041437 was associated with DM in CRC patients. The dominance of the T bearing genotypes in patients with DM was statistically significant ( = 0.038), with an odds ratio of 1.66 (95% confidence interval: 1.03-2.69).
2 型糖尿病（DM）与结直肠癌（CRC）之间的关系已被深入研究，报告表明 DM 患者 CRC 的风险增加。DM 与 CRC 患者的生存之间的关系存在争议。有证据表明，二甲双胍具有抗炎作用，是 DM 患者发生 CRC 的保护因素，二甲双胍治疗与 DM 患者的预后改善相关。在我们的队列中，我们没有发现 DM 或二甲双胍的存在与癌症特异性生存之间存在任何关联，也没有发现与 40 种炎症因子和鸢尾素的血浆水平之间存在任何关系。另一方面，我们发现胰岛素样生长因子结合蛋白 7 单核苷酸多态性 rs2041437 与 CRC 患者的 DM 有关。携带 T 等位基因的基因型在 DM 患者中占主导地位，具有统计学意义（ = 0.038），优势比为 1.66（95%置信区间：1.03-2.69）。
